Personalized proteomics for the diagnosis and treatment of idiopathic inflammatory disease

JAMA Ophthalmology

Volumn 134, Issue 4, 2016, Pages 444-448

  Velez, Gabriel ^a,b   Nathaniel Roybal, C ^a   Colgan, Diana ^a   Tsang, Stephen H ^c,d   Bassuk, Alexander G ^a   Mahajan, Vinit B ^a  

^a UNIVERSITY OF IOWA   (United States)

^b The University of Iowa   (United States)

^c Edward S Harkness Eye Institute   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 4; FLUOCINOLONE ACETONIDE; HLA B27 ANTIGEN; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 23; NERVE GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SOMATOMEDIN BINDING PROTEIN 2; STEM CELL FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; CORTICOSTEROID; CYTOKINE; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; BLOOD CELL COUNT; CHOROIDITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG IMPLANT; ENDOPHTHALMITIS; EPIRETINAL MEMBRANE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HUMAN TISSUE; IDIOPATHIC DISEASE; IMMUNOSUPPRESSIVE TREATMENT; INTERMEDIATE UVEITIS; LABORATORY TEST; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEOMICS; RETINA EDEMA; RETINOPATHY; SIGNAL TRANSDUCTION; UPREGULATION; UVEITIS; VISUAL IMPAIRMENT; VITREORETINOPATHY; VITREOUS BIOPSY; VITREOUS BODY; ADULT; ANALYSIS OF VARIANCE; CASE CONTROL STUDY; DRUG EFFECTS; FOLLOW UP; MALE; METABOLISM; MIDDLE AGED; PROCEDURES; REFERENCE VALUE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VISUAL ACUITY;

ADRENAL CORTEX HORMONES; ADULT; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; CYTOKINES; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PRECISION MEDICINE; PROTEOMICS; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

EID: 84963621275     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2015.5934     Document Type: Article

References (15)

1. Guly CM, Forrester JV. Investigation and management of uveitis. BMJ. 2010;341:c4976.
2. Chang JH, Wakefield D. Uveitis: a global perspective. Ocul Immunol Inflamm. 2002;10(4): 263-279.
3. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053.
4. Dinarello CA. Historical insights into cytokines. Eur J Immunol. 2007;37(suppl 1):S34-S45.
5. Ooi KG, Galatowicz G, Calder VL, Lightman SL. Cytokines and chemokines in uveitis: is there a correlation with clinical phenotype? Clin Med Res. 2006;4(4):294-309.
6. Heckenlively JR, Ferreyra HA. Autoimmune retinopathy: a review and summary. Semin Immunopathol. 2008;30(2):127-134.
7. Cretu D, Prassas I, Saraon P, et al. Identification of psoriatic arthritis mediators in synovial fluid by quantitative mass spectrometry. Clin Proteomics. 2014;11(1):27.
8. Goo YA, Tsai YS, Liu AY, Goodlett DR, Yang CC. Urinary proteomics evaluation in interstitial cystitis/painful bladder syndrome: a pilot study. Int Braz J Urol. 2010;36:464-479.
9. Wen H, Lee T, You S, et al. Urinary metabolite profiling combined with computational analysis predicts interstitial cystitis-associated candidate biomarkers. J Proteome Res. 2015;14(1):541-548.
10. Kunz M, Ibrahim SM. Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity. Mediators Inflamm. 2009;2009:979258.
11. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011; 473(7347):298-307.
12. Hofmaier F, Hauck SM, Amann B, Degroote RL, Deeg CA. Changes in matrix metalloproteinase network in a spontaneous autoimmune uveitis model. Invest Ophthalmol Vis Sci. 2011;52(5): 2314-2320.
13. Romaniuk D, Kimsa MW, Strzalka-Mrozik B, et al. Gene expression of IGF1, IGF1R, and IGFBP3 in epiretinal membranes of patients with proliferative diabetic retinopathy: preliminary study. Mediators Inflamm. 2013;2013:986217.
14. Casaroli-Marano RP, Pagan R, Vilaró S. Epithelial-mesenchymal transition in proliferative vitreoretinopathy: intermediate filament protein expression in retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1999;40(9):2062-2072.
15. Mahajan VB, Skeie JM. Translational vitreous proteomics. Proteomics Clin Appl. 2014;8(3-4): 204-208.